Development of LAG-3/FGL1 blocking peptide and combination with radiotherapy for cancer immunotherapy
Authors:
Open Access
- 18 December 2023
- journal article
- research article
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 14 (3) , 1150-1165
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (U20A20369)
- Science, Technology and Innovation Commission of Shenzhen Municipality (KQTD20190929173853397)
- Basic and Applied Basic Research Foundation of Guangdong Province (2022B1515120085)
This publication has 59 references indexed in Scilit:
- A novel hepatokine, HFREP1, plays a crucial role in the development of insulin resistance and type 2 diabetesDiabetologia, 2016
- Blocking of the PD‐1/PD‐L1 Interaction by a D‐Peptide Antagonist for Cancer ImmunotherapyAngewandte Chemie International Edition, 2015
- Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myelomaJournal for ImmunoTherapy of Cancer, 2015
- Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in miceJournal of Clinical Investigation, 2014
- Recombinant human hepassocin stimulates proliferation of hepatocytes in vivo and improves survival in rats with fulminant hepatic failureGut, 2009
- LAG-3 Regulates Plasmacytoid Dendritic Cell HomeostasisThe Journal of Immunology, 2009
- Role of LAG-3 in Regulatory T CellsImmunity, 2004
- Lymphocyte Activation Gene-3 (CD223) Regulates the Size of the Expanding T Cell Population Following Antigen Activation In VivoThe Journal of Immunology, 2004
- The CD4‐related molecule, LAG‐3 (CD223), regulates the expansion of activated T cellsEuropean Journal of Immunology, 2003
- LAG-3, a novel lymphocyte activation gene closely related to CD4.Journal of Experimental Medicine, 1990